Are pleiotropic effects of statins real?
Alberto Corsini, Nicola Ferri, Michele CortellaroDepartment of Pharmacological Sciences and Department of Clinical Sciences, “Luigi Sacco”, University of Milan, Milan, ItalyAbstract: The clinical benefits of statins are strongly related to their low density lipoproteincholesterol...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2007-11-01
|
Series: | Vascular Health and Risk Management |
Online Access: | https://www.dovepress.com/are-pleiotropic-effects-of-statins-real-peer-reviewed-article-VHRM |
id |
doaj-6ab39bf37f8d4b41baf7388597fa48c0 |
---|---|
record_format |
Article |
spelling |
doaj-6ab39bf37f8d4b41baf7388597fa48c02020-11-25T00:19:55ZengDove Medical PressVascular Health and Risk Management1178-20482007-11-01Volume 36116131527Are pleiotropic effects of statins real?Alberto CorsiniNicola FerriMichele CortellaroAlberto Corsini, Nicola Ferri, Michele CortellaroDepartment of Pharmacological Sciences and Department of Clinical Sciences, “Luigi Sacco”, University of Milan, Milan, ItalyAbstract: The clinical benefits of statins are strongly related to their low density lipoproteincholesterol (LDL-C) lowering properties. However, because mevalonic acid (MVA), the product of 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase reaction, is the precursor not only of cholesterol but also of nonsteroidal isoprenoid compounds, the inhibition of HMG-CoA reductase may result in pleiotropic effects, independent of their hypocholesterolemic properties. The discrimination between the pleiotropic from LDL-C lowering effects may potentially be more evident during the early phase of treatment since plasma MVA levels drop up to 70% within 1–2 hours while a reduction of LDL-C, detectable after 24 hours, became significant after 6–7 days. Therefore, the deprivation of circulating MVA-derived isoprenoids in the early phase of treatment could be the main mechanism responsible for the atheroprotective effect of statins. This early window of protection in the absence of LDL-C lowering suggests that the anti-inflammatory and the pleiotropic properties of statins may have clinical importance. Therefore, acute coronary syndromes could represent a clinical condition for addressing the early benefits of statins therapy, ie, within 24 h of the event, independent of LDL-C lowering.Keywords: anti-inflammatory effects of statins, mevalonate pathway, LDL lowering, acute coronary syndrome, prenylated proteinshttps://www.dovepress.com/are-pleiotropic-effects-of-statins-real-peer-reviewed-article-VHRM |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alberto Corsini Nicola Ferri Michele Cortellaro |
spellingShingle |
Alberto Corsini Nicola Ferri Michele Cortellaro Are pleiotropic effects of statins real? Vascular Health and Risk Management |
author_facet |
Alberto Corsini Nicola Ferri Michele Cortellaro |
author_sort |
Alberto Corsini |
title |
Are pleiotropic effects of statins real? |
title_short |
Are pleiotropic effects of statins real? |
title_full |
Are pleiotropic effects of statins real? |
title_fullStr |
Are pleiotropic effects of statins real? |
title_full_unstemmed |
Are pleiotropic effects of statins real? |
title_sort |
are pleiotropic effects of statins real? |
publisher |
Dove Medical Press |
series |
Vascular Health and Risk Management |
issn |
1178-2048 |
publishDate |
2007-11-01 |
description |
Alberto Corsini, Nicola Ferri, Michele CortellaroDepartment of Pharmacological Sciences and Department of Clinical Sciences, “Luigi Sacco”, University of Milan, Milan, ItalyAbstract: The clinical benefits of statins are strongly related to their low density lipoproteincholesterol (LDL-C) lowering properties. However, because mevalonic acid (MVA), the product of 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase reaction, is the precursor not only of cholesterol but also of nonsteroidal isoprenoid compounds, the inhibition of HMG-CoA reductase may result in pleiotropic effects, independent of their hypocholesterolemic properties. The discrimination between the pleiotropic from LDL-C lowering effects may potentially be more evident during the early phase of treatment since plasma MVA levels drop up to 70% within 1–2 hours while a reduction of LDL-C, detectable after 24 hours, became significant after 6–7 days. Therefore, the deprivation of circulating MVA-derived isoprenoids in the early phase of treatment could be the main mechanism responsible for the atheroprotective effect of statins. This early window of protection in the absence of LDL-C lowering suggests that the anti-inflammatory and the pleiotropic properties of statins may have clinical importance. Therefore, acute coronary syndromes could represent a clinical condition for addressing the early benefits of statins therapy, ie, within 24 h of the event, independent of LDL-C lowering.Keywords: anti-inflammatory effects of statins, mevalonate pathway, LDL lowering, acute coronary syndrome, prenylated proteins |
url |
https://www.dovepress.com/are-pleiotropic-effects-of-statins-real-peer-reviewed-article-VHRM |
work_keys_str_mv |
AT albertocorsini arepleiotropiceffectsofstatinsreal AT nicolaferri arepleiotropiceffectsofstatinsreal AT michelecortellaro arepleiotropiceffectsofstatinsreal |
_version_ |
1725369797618696192 |